These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21175791)

  • 1. Topical agents for idiopathic distal colitis and proctitis.
    Lawrance IC
    J Gastroenterol Hepatol; 2011 Jan; 26(1):36-43. PubMed ID: 21175791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel topical therapies for distal colitis.
    Lawrance IC
    World J Gastrointest Pharmacol Ther; 2010 Oct; 1(5):87-93. PubMed ID: 21577301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ulcerative proctitis: a review of pharmacotherapy and management.
    Lakatos PL; Lakatos L
    Expert Opin Pharmacother; 2008 Apr; 9(5):741-9. PubMed ID: 18345952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical therapy is underused in patients with ulcerative colitis.
    Seibold F; Fournier N; Beglinger C; Mottet C; Pittet V; Rogler G;
    J Crohns Colitis; 2014 Jan; 8(1):56-63. PubMed ID: 23566922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rectal tacrolimus in the treatment of resistant ulcerative proctitis.
    Lawrance IC; Copeland TS
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1214-20. PubMed ID: 18761706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: aminosalicylates for distal colitis.
    Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():41-4. PubMed ID: 16961744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Active and refractory ulcerative proctitis: an update].
    Caselli M G; Pinedo M G; Zúñiga D A; Alvarez L M
    Rev Med Chil; 2010 Jan; 138(1):109-16. PubMed ID: 20361160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Local or systemic treatment of inflammatory bowel diseases?].
    Schmassmann A; Halter F
    Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial.
    D'Arienzo A; Panarese A; D'Armiento FP; Lancia C; Quattrone P; Giannattasio F; Boscaino A; Mazzacca G
    Am J Gastroenterol; 1990 Sep; 85(9):1079-82. PubMed ID: 2202199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
    Cohen RD; Woseth DM; Thisted RA; Hanauer SB
    Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.
    Gross V; Bar-Meir S; Lavy A; Mickisch O; Tulassay Z; Pronai L; Kupcinskas L; Kiudelis G; Pokrotnieks J; Kovács A; Faszczyk M; Razbadauskas A; Margus B; Stolte M; Müller R; Greinwald R;
    Aliment Pharmacol Ther; 2006 Jan; 23(2):303-12. PubMed ID: 16393311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
    Klotz U; Schwab M
    Adv Drug Deliv Rev; 2005 Jan; 57(2):267-79. PubMed ID: 15555742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis.
    Danielsson A; Löfberg R; Persson T; Salde L; Schiöler R; Suhr O; Willén R
    Scand J Gastroenterol; 1992; 27(1):9-12. PubMed ID: 1736348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetarsol in the management of mesalazine-refractory ulcerative proctitis: a tertiary-level care experience.
    Argyriou K; Samuel S; Moran GW
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):183-186. PubMed ID: 30499784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon.
    Frühmorgen P; Demling L
    Hepatogastroenterology; 1980 Dec; 27(6):473-6. PubMed ID: 6110627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: problematic proctitis and distal colitis.
    Gionchetti P; Rizzello F; Morselli C; Campieri M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():93-6. PubMed ID: 15352902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of topical 5-aminosalicylic acid in pregnancy.
    Bell CM; Habal FM
    Am J Gastroenterol; 1997 Dec; 92(12):2201-2. PubMed ID: 9399752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical therapies in inflammatory bowel disease.
    Frei P; Biedermann L; Manser CN; Wilk M; Manz M; Vavricka SR; Rogler G
    Digestion; 2012; 86 Suppl 1():36-44. PubMed ID: 23051725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.